93 unknown, 83 completed, 83 recruiting, 33 terminated. 365 Phase 2, 45 Phase 1, 23 Phase 3.
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy - Glioblastoma, Glioblastoma, IDH-wildtype | Phase 2 | Not yet recruiting | Washington University School of Medicine | 99 | 2026-11-30 | 2026-10-20 |
| SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer SSGJ-706, SPGL008, Chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 220 | 2026-11-01 | 2026-10-15 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-10-19 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma Pemigatinb, PD-1 inhibitors, Chemotherapy - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 154 | 2026-08-20 | 2026-08-26 |
| TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. TACE combined with thermal ablation, Targeted Therapy, Immunotherapy - Gastric Cancer With Liver Metastases | Phase 2 | Not yet recruiting | Shandong Provincial Hospital | 40 | 2026-08-01 | 2026-05-22 |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer Ubamatamab, Chemotherapy, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 43 | 2026-08-01 | 2026-07-10 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer PF-08634404, Chemotherapy - Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Pfizer | 40 | 2026-07-02 | 2026-10-09 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer Camrelizumab, Famitinib Malate, Chemotherapy - Cervical Cancer | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 54 | 2026-06-30 | 2026-06-04 |
| ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab - Anal Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Jennifer Dorth | 33 | 2026-06-19 | 2026-08-14 |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. SHR-A1811, Pertuzumab, trastuzumab - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 100 | 2026-05-01 | 2026-04-14 |
| Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma Chemotherapy, Targeted Systemic Therapy, Immunotherapy - Esophageal Cancer, Gastric (Stomach) Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 290 | 2026-04-29 | 2026-09-10 |
| Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC Vebreltinib, Chemotherapy - Lung Neoplasms | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 19 | 2026-03-30 | 2026-04-29 |
| A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 20 | 2026-03-24 | 2026-08-04 |
| A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy - Locally Advanced Resectable Rectal Cancer | Phase 2 / Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 165 | 2026-03-23 | 2026-05-05 |
| Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC HLX10, Chemotherapy, Nimotuzumab - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2026-03-12 | 2026-03-11 |
Showing 20 of 365. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (49) · Breast Neoplasms (31) · Colorectal Neoplasms (22) · Lung Neoplasms (19) · Pancreatic Neoplasms (19) · Esophageal Neoplasms (17) · Neoplasm Metastasis (16) · Neoplasms (16) · Stomach Neoplasms (16) · Esophageal Squamous Cell Carcinoma (15) · Rectal Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (13) · Ovarian Neoplasms (11) · Head and Neck Neoplasms (10) · Leukemia, Myeloid, Acute (10)
Fudan University (11) · Sun Yat-sen University (10) · Peking Union Medical College Hospital (9) · Pfizer (9) · M.D. Anderson Cancer Center (8) · Shanghai Chest Hospital (6) · National Cancer Institute (NCI) (5) · Sichuan University (5) · Tianjin Medical University Cancer Institute and Hospital (5) · Akeso (4) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · Alliance for Clinical Trials in Oncology (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Eye & ENT Hospital of Fudan University (3) · H. Lee Moffitt Cancer Center and Research Institute (3)
China (145) · United States (110) · France (28) · Italy (23) · Germany (21) · Spain (21) · South Korea (12) · Canada (11) · Netherlands (11) · Belgium (10) · Israel (8) · Taiwan (8) · United Kingdom (8) · Egypt (7) · Japan (7)
Hongmeng Yu, MD,PHD (3) · You Lu, MD (3) · Dominique Elias, MD (2) · Huajun Jin (2) · Hui Liu, Professor (2) · Jiangtao Wang (2) · Keith Cengel, MD, PhD (2) · Mark Stanley Berger, MD (2) · Paul Schwarzenberger, MD (2) · Qijun Qian (2) · Thomas George, MD, FACP (2) · Wen Yu, M.D (2) · A. E van Leeuwen-Stok, PhD (1)
PMID 30062662, PMID 10655437, PMID 11937316, PMID 12177103, PMID 12434281, PMID 14506149, PMID 14645425, PMID 15812833, PMID 16011702, PMID 16078267, PMID 16135463, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 17544337, PMID 17647306, PMID 17909941, PMID 18217208, PMID 18577561, PMID 18990510, PMID 19147777, PMID 19491285, PMID 19515503, PMID 19957326, PMID 19985059, PMID 20375404, PMID 20694800, PMID 20708924, PMID 20921456, PMID 20974795, PMID 21087935, PMID 21171927, PMID 21292687, PMID 21297126, PMID 21297433, PMID 21327862, PMID 21681372, PMID 22132908, PMID 22331797, PMID 22581306, PMID 22747087, PMID 22747092, PMID 22867890, PMID 23043252, PMID 23092726, PMID 23127803, PMID 23536435, PMID 23775348, PMID 23813229
2016 (4), 2025 (4), 2018 (2), 2023 (2), P30CA033572 (2), U10CA180820 (2), 2009 (1), 2014 (1), 2015 (1), 2017 (1), 2019 (1), P30CA006973 (1), P30CA012197 (1), P30CA016672 (1), P30CA036727 (1)